TGF-β信号通路在肿瘤微环境中的作用及其靶向药物开发进展

吴婧; 李明春; 王春燕

doi:10.6039/j.issn.1001-0408.2024.19.21

您当前的位置：

首页 >

文章列表页 >

TGF-β信号通路在肿瘤微环境中的作用及其靶向药物开发进展

综述 | 更新时间：2024-10-11

- TGF-β信号通路在肿瘤微环境中的作用及其靶向药物开发进展
- Effects of TGF-β signaling pathway in the tumor microenvironment and development advance in targeted drug
- 中国药房 2024年35卷第19期页码：2444-2448
- 作者机构：
  
  中国人民解放军海军第九七一医院药剂科，山东青岛　266071
- 作者简介：
  
  副主任药师，硕士。研究方向：生物医学、药物化学。E-mail：wj108code@163.com
  主任药师，硕士。研究方向：临床药学。E-mail：wangchunyan401@126.com
- 基金信息：
  
  青岛市医药卫生科研指导项目(2022-WJZD213)
- DOI：10.6039/j.issn.1001-0408.2024.19.21
  中图分类号： R979.1
- 纸质出版日期：2024-10-15，
  
  收稿日期：2024-03-15，
  
  修回日期：2024-08-12，
- 稿件说明：
移动端阅览
吴婧,李明春,王春燕.TGF-β信号通路在肿瘤微环境中的作用及其靶向药物开发进展 ^Δ[J].中国药房,2024,35(19):2444-2448.

WU Jing,LI Mingchun,WANG Chunyan.Effects of TGF-β signaling pathway in the tumor microenvironment and development advance in targeted drug[J].ZHONGGUO YAOFANG,2024,35(19):2444-2448.
吴婧,李明春,王春燕.TGF-β信号通路在肿瘤微环境中的作用及其靶向药物开发进展 ^Δ[J].中国药房,2024,35(19):2444-2448. DOI： 10.6039/j.issn.1001-0408.2024.19.21.

WU Jing,LI Mingchun,WANG Chunyan.Effects of TGF-β signaling pathway in the tumor microenvironment and development advance in targeted drug[J].ZHONGGUO YAOFANG,2024,35(19):2444-2448. DOI： 10.6039/j.issn.1001-0408.2024.19.21.

摘要

转化生长因子β（TGF-β）信号通路失调与包括肿瘤在内的多种病理状况的发生和发展有关。在肿瘤发生早期，TGF-β作为一种抗增殖和促分化因子，能发挥抑癌作用；而在晚期肿瘤中，TGF-β可通过对肿瘤微环境的作用（如促血管生成、促纤维化、免疫抑制和调节细胞代谢）刺激肿瘤进展和转移。目前已有多种TGF-β抑制剂进入临床研究阶段，包括单克隆抗体、配体陷阱、小分子抑制剂、反义寡核苷酸、双特异性抗体和肿瘤疫苗等几大类别，但目前仍没有相关药物被批准用于临床癌症治疗。准确筛选潜在获益患者、与免疫检查点抑制剂联用等是其今后的发展方向。

Abstract

Dysregulation of transforming growth factor β （TGF-β） signaling pathway is related to the occurrence and development of various pathological conditions， including tumors. In the early stage of tumorigenesis， TGF-β， as an anti-proliferation and pro-differentiation factor， plays an anticancer role. In advanced tumors， TGF-β can stimulate tumor progression and metastasis through its effect on the tumor microenvironment （such as promoting angiogenesis， fibrosis， immune suppression， and regulating cellular metabolism）. A variety of TGF-β signaling pathway inhibitors have been tested in clinical trials， including monoclonal antibodies， ligand traps， small molecule inhibitors， antisense oligonucleotides， bispecial antibodies， and tumor vaccines， but no related drugs are currently approved for cancer treatment clinically. Accurately screening potential benefit patients and combining it with immune checkpoint inhibitors are its future development directions.

关键词

转化生长因子β肿瘤微环境靶向治疗

Keywords

tumor microenvironmenttargeted therapy

references

DENG Z Q，FAN T，XIAO C，et al. TGF-β signaling in health，disease，and therapeutics[J]. Signal Transduct Target Ther，2024，9（1）：61-101.

ZHAO H，WEI J，SUN J. Roles of TGF-β signaling pathway in tumor microenvironment and cancer therapy[J]. Int Immunopharm，2020，89（Pt B）：107101-107110.

COLAK S，TEN DIJKE P. Targeting TGF-β signaling in cancer[J]. Trends Cancer，2017，3（1）：56-71.

BOULTER L，BULLOCK E，MABRUK Z，et al. The fibrotic and immune microenvironments as targetable dri- vers of metastasis[J]. Br J Cancer，2021，124（1）：27-36.

MATSUOKA T，YASHIRO M. The role of the transfor- ming growth factor-β signaling pathway in gastrointestinal cancers[J]. Biomolecules，2023，13（10）：1551.

TSCHERNIA N P，GULLEY J L. Tumor in the crossfire：inhibiting TGF-β to enhance cancer immunotherapy[J]. BioDrugs，2022，36（2）：153-180.

FENG J F，TANG D H，WANG J，et al. SHR-1701，a bifunctional fusion protein targeting PD-L1 and TGF-β，for recurrent or metastatic cervical cancer：a clinical expansion cohort of a phase Ⅰ study[J]. Clin Cancer Res，2022，28（24）：5297-5305.

HELDIN C H，MOUSTAKAS A. Signaling receptors for TGF-β family members[J]. Cold Spring Harb Perspect Biol，2016，8（8）：a022053.

MORIKAWA M，DERYNCK R，MIYAZONO K. TGF-β and the TGF-β family：context-dependent roles in cell and tissue physiology[J]. Cold Spring Harb Perspect Biol，2016，8（5）：a021873.

MOUSTAKAS A，HELDIN C H. Non-smad TGF-β signals[J]. J Cell Sci，2005，118（Pt 16）：3573-3584.

LIU Z W，ZHANG Y M，ZHANG L Y，et al. Duality of interactions between TGF-β and TNF-α during tumor formation[J]. Front Immunol，2021，12：810286.

PAPA E，WELLER M，WEISS T，et al. Negative control of the HGF/c-MET pathway by TGF-β：a new look at the regulation of stemness in glioblastoma[J]. Cell Death Dis，2017，8（12）：3210.

LOURENÇO A R，ROUKENS M G，SEINSTRA D，et al. C/EBPα is crucial determinant of epithelial maintenance by preventing epithelial-to-mesenchymal transition[J]. Nat Commun，2020，11（1）：785.

FANG L L，LI Y R，WANG S J，et al. TGF-β1 induces VEGF expression in human granulosa-lutein cells：a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome[J]. Exp Mol Med，2020，52（3）：450-460.

TURATI M，MOUSSET A，ISSA N，et al. TGF-β media- ted drug resistance in solid cancer[J]. Cytokine Growth Factor Rev，2023，71：54-65.

KARAGIANNIS G S，POUTAHIDIS T，ERDMAN S E，et al. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue[J]. Mol Cancer Res，2012，10（11）：1403-1418.

TSE J M，CHENG G，TYRRELL J A，et al. Mechanical compression drives cancer cells toward invasive phenotype[J]. Proc Natl Acad Sci U S A，2012，109（3）：911-916.

NIXON B G，GAO S Y，WANG X X，et al. TGF-β control of immune responses in cancer：a holistic immunooncology perspective[J]. Nat Rev Immunol，2023，23（6）：346-362.

GAO S Y，HSU T W，LI M O. Immunity beyond cancer cells：perspective from tumor tissue[J]. Trends Cancer，2021，7（11）：1010-1019.

SHI X K，YANG J，DENG S Z，et al. TGF-β signaling in the tumor metabolic microenvironment and targeted therapies[J]. J Hematol Oncol，2022，15（1）：135.

ANGIONI R，SÁNCHEZ-RODRÍGUEZ R，VIOLA A， et al. TGF-β in cancer：metabolic driver of the tolerogenic crosstalk in the tumor microenvironment[J]. Cancers，2021，13（3）：401.

LIU S J，REN J，TEN DIJKE P. Targeting TGF-β signal transduction for cancer therapy[J]. Signal Transduct Target Ther，2021，6：8.

MORRIS J C，TAN A R，OLENCKI T E，et al. Phase Ⅰ study of GC1008 （Fresolimumab）：a human anti-transforming growth factor-beta （TGF-β） monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma[J]. PLoS One，2014，9（3）：e90353.

ZHONG Z J，CARROLL K D，POLICARPIO D，et al. Anti-transforming growth factor beta receptor Ⅱ antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer，stroma，and immune cells[J]. Clin Cancer Res，2010，16（4）：1191-1205.

TOLCHER A W，BERLIN J D，COSAERT J，et al. A phase 1 study of anti-TGF-β receptor type-Ⅱ monoclonal antibody LY3022859 in patients with advanced solid tumors[J]. Cancer Chemother Pharmacol，2017，79（4）：673-680.

MARTIN C J，DATTA A，LITTLEFIELD C，et al. Selective inhibition of TGF-β1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape[J]. Sci Transl Med，2020，12（536）：eaay8456.

YAP T A，BARVE M A，GAINOR J F，et al. First-in-human phase 1 trial （DRAGON） of SRK-181，a potential first-in-class selective latent TGF-β1 inhibitor，alone or in combination with anti-PD-（L）1 treatment in patients with advanced solid tumors[J]. J Clin Oncol，2021，39（Suppl. 15）：TPS3146.

BAUER T M，LIN C C，GREIL R，et al. Phase Ⅰb study of the anti-TGF-β monoclonal antibody （MAb） NIS793 combined with spartalizumab （PDR001），a PD-1 inhibitor，in patients （pts） with advanced solid tumors[J]. J Clin Oncol，2021，39（Suppl. 15）：2509.

GRECO R，QU H J，QU H，et al. Pan-TGF-β inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade[J]. Oncoimmunology，2020，9（1）：1811605.

MASCARENHASJ，MIGLIACCIO A R，KOSIOREK H，et al. A phaseⅠb trial of AVID200，a TGF-β1/3 trap，in patients with myelofibrosis[J]. Clin Cancer Res，2023，29（18）：3622-3632.

YAP T A，LAKHANI N J，ARAUJO D V，et al. AVID200，first-in-class TGF-beta 1 and 3 selective and potent inhibitor：safety and biomarker results of a phase Ⅰ monotherapy dose-escalation study in patients with advanced solid tumors[J]. J Clin Oncol，2020，38（Suppl. 15）：3587.

FAIVRE S，SANTORO A，KELLEY R K，et al. Novel transforming growth factor beta receptor Ⅰ kinase inhibitor galunisertib （LY2157299） in advanced hepatocellular carcinoma[J]. Liver Int，2019，39（8）：1468-1477.

MELISI D，GARCIA-CARBONERO R，MACARULLA T，et al. TGF-β receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer[J]. Cancer Chemother Pharmacol，2019，83（5）：975-991.

NADAL E，SALEH M，AIX S P，et al. A phase Ⅰb/Ⅱ study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer[J]. BMC Cancer，2023，23（1）：708-721.

YAP T A，VIEITO M，BALDINI C，et al. First-in-human phase Ⅰ study of a next-generation，oral，TGF-β receptor 1 inhibitor，LY3200882，in patients with advanced cancer[J]. Clin Cancer Res，2021，27（24）：6666-6676.

JUNG S Y，HWANG S，CLARKE J M，et al. Pharmacokinetic characteristics of vactosertib，a new activin receptor-like kinase 5 inhibitor，in patients with advanced solid tumors in a first-in-human phase 1 study[J]. Invest New Drugs，2020，38（3）：812-820.

LEE K W，PARK Y S，AHN J B，et al. Safety and anti-tumor activity of the transforming growth factor beta receptor Ⅰ kinase inhibitor，vactosertib，in combination with pembrolizumab in patients with metastatic colorectal or gastric cancer[J]. J Immunother Cancer，2020，8（Suppl. 3）：A358.

JASCHINSKI F，ROTHHAMMER T，JACHIMCZAK P，et al. The antisense oligonucleotide trabedersen （AP 12009） for the targeted inhibition of TGF-β2[J]. Curr Pharm Biotechnol，2011，12（12）：2203-2213.

BOGDAHN U，HAU P，STOCKHAMMER G，et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen：results of a randomized and controlled phase Ⅱb study[J]. Neuro Oncol，2011，13（1）：132-142.

GONZALEZ-JUNCA A，DRISCOLL K E，PELLICCIOTTA I，et al. Autocrine TGF-β is a survival factor for monocytes and drives immunosuppressive lineage commitment[J]. Cancer Immunol Res，2019，7（2）：306-320.

COURAU T，NEHAR-BELAID D，FLOREZ L，et al. TGF-β and VEGF cooperatively control the immunotole- rant tumor environment and the efficacy of cancer immunotherapies[J]. JCI Insight，2016，1（9）：e85974.

BURVENICH I J G，GOH Y W，GUO N，et al. Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRⅡ fusion protein bintrafusp alfa[J]. Eur J Nucl Med Mol Imag，2021，48（10）：3075-3088.

CHAN M K，CHUNG J Y，TANG P C，et al. TGF-β signaling networks in the tumor microenvironment [J]. Cancer Lett，2022，550：215925.

GIACCONE G，BAZHENOVA L A，NEMUNAITIS J， et al. A phase Ⅲ study of belagenpumatucel-L，an allogeneic tumor cell vaccine，as maintenance therapy for non-small cell lung cancer[J]. Eur J Cancer，2015，51（16）：2321-2329.

WALTER A，ROCCONI R P，MONK B J，et al. Gemogenovatucel-T （Vigil） maintenance immunotherapy：3-year survival benefit in homologous recombination proficient （HRP） ovarian cancer[J]. Gynecol Oncol，2021，163（3）：459-464.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

外泌体载药系统的研究进展

胆红素纳米颗粒的药理作用研究进展

巨噬细胞膜仿生纳米递药系统在疾病靶向治疗中的应用

化疗联合分子靶向药物治疗三阴性乳腺癌的研究进展

分子靶向药物治疗非小细胞肺癌的策略